Blandini F - Search Results

1

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.

Ambrosi G, Ghezzi C, Zangaglia R, Levandis G, Pacchetti C, Blandini F. Ambrosi G, et al. Among authors: blandini f. Neurobiol Dis. 2015 Oct;82:235-242. doi: 10.1016/j.nbd.2015.06.008. Epub 2015 Jun 19. Neurobiol Dis. 2015. PMID: 26094596

2

Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type.

Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G. Martignoni E, et al. Among authors: blandini f. J Neural Transm Park Dis Dement Sect. 1992;4(3):191-205. doi: 10.1007/BF02260903. J Neural Transm Park Dis Dement Sect. 1992. PMID: 1320891

3

Glutamate and Parkinson's disease.

Blandini F, Porter RH, Greenamyre JT. Blandini F, et al. Mol Neurobiol. 1996 Feb;12(1):73-94. doi: 10.1007/BF02740748. Mol Neurobiol. 1996. PMID: 8732541 Review.

4

Simultaneous determination of L-dopa and 3-O-methyldopa in human platelets and plasma using high-performance liquid chromatography with electrochemical detection.

Blandini F, Martignoni E, Pacchetti C, Desideri S, Rivellini D, Nappi G. Blandini F, et al. J Chromatogr B Biomed Sci Appl. 1997 Oct 24;700(1-2):278-82. doi: 10.1016/s0378-4347(97)00307-1. J Chromatogr B Biomed Sci Appl. 1997. PMID: 9390741

5

Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.

Martignoni E, Blandini F, Godi L, Desideri S, Pacchetti C, Mancini F, Nappi G. Martignoni E, et al. Among authors: blandini f. Free Radic Biol Med. 1999 Aug;27(3-4):428-37. doi: 10.1016/s0891-5849(99)00075-1. Free Radic Biol Med. 1999. PMID: 10468218 Clinical Trial.

6

Functional changes of the basal ganglia circuitry in Parkinson's disease.

Blandini F, Nappi G, Tassorelli C, Martignoni E. Blandini F, et al. Prog Neurobiol. 2000 Sep;62(1):63-88. doi: 10.1016/s0301-0082(99)00067-2. Prog Neurobiol. 2000. PMID: 10821982 Review.

7

Plasma homocysteine and l-dopa metabolism in patients with Parkinson disease.

Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Samuele A, Nappi G. Blandini F, et al. Clin Chem. 2001 Jun;47(6):1102-4. Clin Chem. 2001. PMID: 11375298 No abstract available.

8

COMT inhibition and safety.

Martignoni E, Blandini F, Pacchetti C, Nappi G. Martignoni E, et al. Among authors: blandini f. Funct Neurol. 2001;16(4 Suppl):135-40. Funct Neurol. 2001. PMID: 11996508 Review. No abstract available.

9

Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease.

Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E. Blandini F, et al. J Neural Transm (Vienna). 2003 Aug;110(8):911-22. doi: 10.1007/s00702-003-0004-z. J Neural Transm (Vienna). 2003. PMID: 12898346

10

Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment.

Blandini F, Cosentino M, Mangiagalli A, Marino F, Samuele A, Rasini E, Fancellu R, Tassorelli C, Pacchetti C, Martignoni E, Riboldazzi G, Calandrella D, Lecchini S, Frigo G, Nappi G. Blandini F, et al. J Neural Transm (Vienna). 2004 Aug;111(8):1017-30. doi: 10.1007/s00702-004-0123-1. Epub 2004 Mar 19. J Neural Transm (Vienna). 2004. PMID: 15254790 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

181 results

Search Page